PI Industries: Pioxaniliprole NCE filing and approvals 2026

Stock snapshot and what drew attention

PI Industries (NSE: PIIND, BSE: 523642), a pesticides and agrochemicals player, was quoted at Rs 2,465 on the NSE, up Rs 45.10 (1.86%) as of 04 Sep, 4:00 PM. The same data set also lists the company’s market capitalisation at Rs 37,398.516087 crore, based on the latest share price. While daily price moves are often noise, the update stood out because it coincided with a series of product and regulatory developments discussed in recent coverage.

PI Industries Limited is described as an Indian chemical and crop protection enterprise headquartered in Gurugram, Haryana. The company’s latest narrative is being shaped by a mix of innovation-led R&D announcements and ongoing regulatory clearances in crop protection products.

First indigenous NCE registration filing: Pioxaniliprole

A key development flagged in the material is PI Industries’ first indigenous New Chemical Entity (NCE) registration filing in India for “PIOXANILIPROLE”. The filing is positioned as the company’s first indigenous NCE entry, marking a notable step in its innovation pipeline.

The coverage also states that the first indigenous NCE molecule Pioxaniliprole is expected to be commercialised in India following regulatory clearance. This links the R&D milestone directly to the domestic regulatory process, which typically determines launch timing in crop protection.

Commercial execution alongside innovation

Alongside the NCE update, PI Industries cited continued commercial progress. The company said commercialisation momentum was maintained with five new CSM molecules exported and three domestic agri-brands launched. The combination suggests parallel priorities: scaling contract manufacturing/export execution while expanding branded presence at home.

These statements matter because NCE-led innovation usually has longer lead times, while CSM and domestic brands can contribute nearer-term commercial traction. The article material does not provide revenue figures for these items, but it explicitly notes the number of molecules exported and brands launched.

R&D spending and pipeline scale

PI Industries’ innovation push is linked to a stated $100 million research investment that is described as fuelling ninety new assets, “leading with Pioxaniliprole.” In practical terms, this positions Pioxaniliprole as the first high-visibility outcome from a broader pool of R&D assets.

The company’s first innovative asset is described as an insecticide called Pioxaniliprole, intended for crops such as corn and rice. It is expected to launch in the domestic market this year after securing regulatory approvals, and later in export markets such as the US and Latin America through partnerships.

Launch sequencing and target markets mentioned

The coverage outlines an expected regulatory and market sequence: India approvals this year, a plan to file for the US next year, and Brazil in the subsequent year. It also references overseas markets including the US, Mexico and Brazil, indicating where PI expects meaningful addressable demand.

A company estimate in the provided text puts the addressable market at about $100 million across India and overseas markets including the US, Mexico and Brazil. Separately, Chinese-language press coverage attributed to the company’s vice chairman and managing director mentions the segment market size is not less than $100 million, while adding that the reachable market could exceed several billion dollars.

Regulatory clearances: what was approved for PI Industries

Beyond the NCE filing narrative, the material includes a set of India registration approvals under the insecticide and technical registration framework. PI Industries is specifically mentioned as receiving approvals for:

• Dicloromezotiaz Technical 95.5% (technical registration)
• Dicloromezotiaz 20% SC formulation (insecticide), with intended pest and crop uses listed
• Pyroxasulfone 85% WG, with weeds and target crops specified

The Dicloromezotiaz 20% SC formulation is intended for managing pests including green semilooper, pod borer, tobacco caterpillar, and diamondback moth, with crops mentioned including soybean, cabbage, chilli and tomato.

Key facts table

Shareholding signals from the provided snapshot

The shareholding summary shown in the data indicates promoters at 46.09% across Jun 2025, Sep 2025, Dec 2025, Mar 2026 and Jun 2026, with investors at 53.91% across the same quarters. Within named holders listed in the snapshot, some positions are shown for Mar 2026 and Jun 2026, including Axis Mutual Fund Trustee at 2.02% (Mar 2026) and 1.90% (Jun 2026), and ICICI Prudential at 7.61% (Jun 2026).

The same list also shows Investor Education and Protection Fund at 0.11% in Jun 2025, Dec 2025, and Mar 2026, and 0.10% in Jun 2026. It lists LICI New Pension Plus at 6.33% (Dec 2025) and 7.01% (Jun 2026), and Kotak Mahindra Trustee at 2.58% (Jun 2026).

Approvals involving PI Industries (from the tables)

Market impact: what investors can verify from the numbers

From a market-data standpoint, the only explicit movement provided is the stock’s 1.86% rise to Rs 2,465 at the stated timestamp. The market cap is explicitly stated at Rs 37,398.516087 crore. On the business side, the market-facing implication is that PI is pairing an innovation milestone (first indigenous NCE filing) with a sequence of India approvals for other products and formulations.

Separately, the shareholding snapshot shows promoter holding steady at 46.09% across the listed quarters, which can be relevant for investors tracking ownership stability. The institutional entries shown in the snapshot provide additional context on disclosed positions, but the dataset does not include a full ownership register or changes beyond the listed quarters.

Why the Pioxaniliprole milestone matters in context

The coverage repeatedly frames Pioxaniliprole as India’s first discovered molecule for crop protection, “discovered, developed and proven in India by PI Industries.” If commercialised after regulatory clearance, the molecule could become a reference point for domestic agrochemical innovation, separate from routine registration approvals of existing actives and formulations.

At the same time, the registration and approval ecosystem is active, as shown by approvals for multiple companies and products in the same set of tables. For PI Industries, the simultaneous presence of (1) a first-of-its-kind NCE filing and (2) approvals for products such as Dicloromezotiaz and Pyroxasulfone highlights a pipeline that includes both novel innovation and ongoing portfolio expansion.

Conclusion

PI Industries’ latest updates combine a clear innovation marker - the Pioxaniliprole NCE registration filing in India - with regulatory approvals for other crop protection products and formulations. The stock was last quoted at Rs 2,465 with a stated market cap of Rs 37,398.516087 crore in the provided snapshot. The next identifiable milestones in the narrative are the company’s expectation of India regulatory approvals this year for Pioxaniliprole, followed by planned filings for the US next year and Brazil thereafter.